Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Dyslipidemia and
fatty liver
are important components of the metabolic syndrome and are the factors most commonly associated with the development of nonalcoholic
fatty liver
disease. Delayed and excessive insulin secretion in response to food intake is a key element in the onset of these risk factors.
Nateglinide
(
NAT
) is known to restore early-phase insulin secretion. We assessed the effect of
NAT
on postprandial hypertriglyceridemia and
fatty liver
in type 2 diabetic Goto-Kakizaki (GK) rats. The GK rats fed a high-fat diet containing 30% beef tallow twice a day were administered either the vehicle alone or
NAT
(50 mg/kg) before each meal for 12 weeks. Delayed insulin secretion and an increase of total insulin release were caused by feeding 30% beef tallow to the rats. This diet also induced postprandial hypertriglyceridemia and increased the hepatic triglyceride content. Treatment with
NAT
restored early-phase insulin secretion without any increase of total insulin release and also reduced postprandial hypertriglyceridemia and the hepatic triglyceride content. There was up-regulation of the hepatic expression of peroxisome proliferators-activated receptor alpha and its downstream enzymes after 12 weeks of
NAT
treatment, as well as normalization of the plasma total ketone body level. Furthermore,
NAT
also up-regulated hepatic expression of the adiponectin receptor AdipoR2, although there was no effect on the plasma adiponectin level. These findings indicate that long-term treatment with
NAT
prevented the development of
fatty liver
through the up-regulation of hepatic lipid oxidation pathways. Restoration of early-phase insulin secretion and suppression of recurrent postprandial hypertriglyceridemia might be involved in these effects of
NAT
. The present results may support the use of
NAT
to prevent the onset and progression of the metabolic syndrome and chronic liver disease.
...
PMID:Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet. 1807 71
